MeiraGTx reports positive Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia; 6/7 patients improved

MeiraGTx Holdings plc

6 of 7 participants achieved clinically meaningful improvement in xerostomia symptoms on two validated PRO measures.
One participant maintained maximal symptom improvement score of 7 at 24 months post-treatment.
AAV-hAQP1 well tolerated with no dose-limiting toxicities or serious adverse events reported.
Company plans to initiate a randomized, double-blind, placebo-controlled Phase 2 study in H2 2022.
Target market: ~170,000 US patients with grade 2/3 RIX; no new treatments approved in >20 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.